A Phase 1/2, Multicenter, Non-Randomized, Open Label Clinical Trial of NPC-08 Implant in Patients Undergoing Surgery for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme.

Trial Profile

A Phase 1/2, Multicenter, Non-Randomized, Open Label Clinical Trial of NPC-08 Implant in Patients Undergoing Surgery for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Oct 2013

At a glance

  • Drugs Carmustine polifeprosan 20 wafer (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jan 2013 Results have been reported in an Eisai and Nobelpharma media release.
    • 05 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Sep 2010 Planned end date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top